BioSpace News Archive

Genialis, a leader in applied data science for the development of precision medicines, today announced together with the Bioinformatics Laboratory at the University of Ljubljana that the organizations have entered into a Sponsored Research Agreement to develop new algorithms and methods to better assign patients to therapeutic options based on disease subtypes,

As previously announced, SIXW established a Service Agreement with UofA and LKS to facilitate the development of AMIPs™ (the “Service Agreement”).

The Inamori Foundation and the Kyoto Symposium Organization announced a detailed schedule for the 20th annual Kyoto Prize Symposium, featuring unique educational events with two university co-hosts – University of California San Diego and Point Loma Nazarene University.

Center for Information and Study on Clinical Research Participation (CISCRP) Announces Second Annual AWARE for All 2021 Virtual Event Series The nonprofit organization aims to boost awareness and interest around clinical trial research through FREE interactive, educational events

BOA Biomedical, a Miraki™ Innovation company, focused on rapidly diagnosing and treating some of the world’s deadliest infectious diseases has announced that the company will begin its First in Human clinical trial for GARNET.

Alcami, a global pharmaceutical contract development and manufacturing organization (CDMO), announced today that its Board of Directors has appointed Patrick Walsh

Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Susan Stimson has been appointed as an independent member to the company’s Board of Directors.

Xcovery Holdings, Inc., an oncology focused bio-pharmaceutical company, today announced that Giovanni Selvaggi, M.D., has been appointed as the Chief Executive Officer (CEO), replacing Li Mao, M.D., who is leaving for personal reasons

ImmunogenX is happy to announce the successful completion of the CeliacShield™ trial (NCT03585478). This gluten-challenge trial measured several outcomes including histology, symptoms, serology, and gluten in urine

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today reported important corporate events and its financial results for the full year and the fourth quarter ended December 31, 2020.